RPG Life Sciences Q2 FY27 Revenue up 16.5% to ₹211.6 Cr; API business expands
RPG Life Sciences reported Q2 FY27 revenue of ₹211.6 crore, a 16.5% increase year-on-year. Adjusted EBITDA grew 15% to ₹50.1 crore. Domestic Formulations outperformed the market, and the flagship brand Naprosyn crossed ₹100 crore in sales. The company expanded its API business through strategic investments and acquisitions.
Significant revenue growth, milestone achievements (₹200 crore quarterly revenue, ₹100 crore brand sales), and strategic expansion of the API business indicate a substantial positive impact on the company's performance and future prospects.
The company reported strong revenue growth, margin expansion, and outperformance in key business segments, along with strategic expansion in its API business.
RPG Life Sciences Limited announced its financial results for the quarter and half-year ended September 30, 2026. The company achieved a significant milestone by crossing the ₹200 crore quarterly revenue mark, with Revenue from Operations growing by 16.5% to ₹211.6 crore in Q2 FY27, compared to ₹181.7 crore in Q2 FY26. For the half-year ended September 30, 2026 (H1 FY27), Revenue from Operations stood at ₹407.3 crore, a 16.2% increase from ₹350.6 crore in H1 FY26.
The company also reported robust gross margin expansion of 260 basis points in Q2, despite a challenging external environment. Adjusted EBITDA, excluding one-off API acquisition and restructuring costs of ₹5.5 crore, grew by 15% to ₹50.1 crore in Q2 FY27, resulting in a 23.7% EBITDA margin, compared to 24.0% year-on-year. For H1 FY27, Adjusted EBITDA increased by 16.1% to ₹97.9 crore from ₹84.3 crore in H1 FY26.
The Domestic Formulations business demonstrated strong performance, becoming the 4th fastest-growing company in the Indian Pharmaceutical Market (IPM) and achieving a "Top 50" rank. The flagship brand, Naprosyn, surpassed ₹100 crore in sales.
International Formulations revived its growth trajectory, growing at 6.4% in Q2 and 7.0% in H1. The API business organically delivered a strong quarter with sales of ₹27.5 crore in Q2 and ₹54.1 crore in H1. RPG Life Sciences transferred its API business to RPG Active Pharma and onboarded InvAscent as a strategic investor. The company also completed the acquisitions of two API plants, Actis Generics and Raghava Lifesciences, significantly expanding its manufacturing capacity and product pipeline.
Mr. Ashok Nair, Managing Director, RPG Life Sciences Ltd., commented on the results, stating, "We have delivered another strong quarter with 16.5% revenue growth and 15% adjusted EBITDA growth, while maintaining healthy margins despite external cost pressures. More importantly, the quality of growth remains strong." He highlighted the focus on integration and value creation for the expanded API business through higher asset utilization, deeper customer engagement, international expansion, and cost improvement.
What to do with a filing like this
RPG Life Sciences Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by RPG Life Sciences Limited. Read the original for the full detail.